trial · primary record
Tislelizumab
Non-small Cell Lung Cancer Metastatic
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 230 |
| Primary completion | 2031-10-30 |
| Primary endpoint | Progression-free survival |
| Registry ID | NCT07715396 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:18.426Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07715396
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.